NO20083207L - Inhibitorer av IAP - Google Patents

Inhibitorer av IAP

Info

Publication number
NO20083207L
NO20083207L NO20083207A NO20083207A NO20083207L NO 20083207 L NO20083207 L NO 20083207L NO 20083207 A NO20083207 A NO 20083207A NO 20083207 A NO20083207 A NO 20083207A NO 20083207 L NO20083207 L NO 20083207L
Authority
NO
Norway
Prior art keywords
iap
inhibitors
compounds
useful
treatment
Prior art date
Application number
NO20083207A
Other languages
English (en)
Norwegian (no)
Inventor
Jr Lewis J Gazzard
Vickie Hsiao-Wei Tsui
Michael F T Koehler
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of NO20083207L publication Critical patent/NO20083207L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Steroid Compounds (AREA)
NO20083207A 2005-12-19 2008-07-18 Inhibitorer av IAP NO20083207L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75180105P 2005-12-19 2005-12-19
PCT/US2006/062335 WO2007106192A2 (en) 2005-12-19 2006-12-19 Inhibitors of iap

Publications (1)

Publication Number Publication Date
NO20083207L true NO20083207L (no) 2008-09-17

Family

ID=38509952

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20083207A NO20083207L (no) 2005-12-19 2008-07-18 Inhibitorer av IAP

Country Status (13)

Country Link
US (2) US8247557B2 (enExample)
EP (1) EP1973899A4 (enExample)
JP (1) JP5155184B2 (enExample)
KR (1) KR20080080203A (enExample)
CN (1) CN101374829A (enExample)
AU (1) AU2006340014B2 (enExample)
CA (1) CA2632807A1 (enExample)
IL (1) IL191997A0 (enExample)
NO (1) NO20083207L (enExample)
NZ (1) NZ594746A (enExample)
RU (1) RU2451025C2 (enExample)
WO (1) WO2007106192A2 (enExample)
ZA (1) ZA200805152B (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1773766B1 (en) 2004-07-15 2014-04-02 Tetralogic Pharmaceuticals Corporation Iap binding compounds
ATE477254T1 (de) 2004-12-20 2010-08-15 Genentech Inc Pyrrolidine als inhibitoren von iap
BRPI0607988A2 (pt) 2005-02-25 2009-10-27 Tetralogic Pharmaceuticals composto, composição farmacêutica, e método para induzir apoptose em uma célula
US7772177B2 (en) 2005-05-18 2010-08-10 Aegera Therapeutics, Inc. BIR domain binding compounds
JP2009512719A (ja) 2005-10-25 2009-03-26 アエゲラ セラピューティクス インコーポレイテッド Ｉａｐｂｉｒドメイン結合化合物
CN101374829A (zh) 2005-12-19 2009-02-25 健泰科生物技术公司 Iap的抑制剂
TWI543988B (zh) 2006-03-16 2016-08-01 科學製藥股份有限公司 結合於細胞凋亡抑制蛋白（ｉａｐ）之桿狀病毒ｉａｐ重複序列（ｂｉｒ）區域之化合物
AU2007250443B2 (en) 2006-05-16 2013-06-13 Pharmascience Inc. IAP BIR domain binding compounds
WO2008014252A2 (en) * 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Iap inhibitors
US20100144650A1 (en) * 2006-07-24 2010-06-10 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
AR063943A1 (es) * 2006-07-24 2009-03-04 Tetralogic Pharmaceuticals Cor Dipeptidos antagonistas de iap, una composicion farmaceutica que los comprende y el uso de los mismos para el tratamiento del cancer.
RU2009117701A (ru) * 2006-10-12 2010-11-20 Новартис АГ (CH) Производные пирролидина в качестве ингибиторов iap
JP2010510245A (ja) * 2006-11-21 2010-04-02 スミスクライン ビーチャム コーポレーション 抗ウイルス化合物
JP2010513561A (ja) * 2006-12-19 2010-04-30 ジェネンテック， インコーポレイテッド Ｉａｐのイミダゾピリジンインヒビター
CN101687787A (zh) * 2007-04-30 2010-03-31 健泰科生物技术公司 Iap的抑制剂
JP2010528587A (ja) * 2007-05-07 2010-08-26 テトラロジック ファーマシューティカルズ コーポレーション アポトーシス阻害タンパク質のアンタゴニストに対する感受性のバイオマーカーとしてＴＮＦα遺伝子の発現を用いる方法
KR20100110870A (ko) * 2008-01-11 2010-10-13 제넨테크, 인크. Ｉａｐ의 억제제
EP2303841A1 (en) 2008-07-14 2011-04-06 Gilead Sciences, Inc. Oxindolyl inhibitor compounds
NZ590550A (en) 2008-08-02 2013-05-31 Genentech Inc Inhibitors of Apoptosis (IAP) for treating cancer
US20110218211A1 (en) * 2008-08-16 2011-09-08 Genentech, Inc. Azaindole inhibitors of iap
EP2440519A1 (en) 2009-06-08 2012-04-18 Gilead Sciences, Inc. Alkanoylamino benzamide aniline hdac inihibitor compounds
CA2763167A1 (en) 2009-06-08 2010-12-16 Gilead Sciences, Inc. Cycloalkylcarbamate benzamide aniline hdac inhibitor compounds
US8283372B2 (en) 2009-07-02 2012-10-09 Tetralogic Pharmaceuticals Corp. 2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic
TW201109335A (en) 2009-08-04 2011-03-16 Takeda Pharmaceutical Heterocyclic compounds
WO2011075615A1 (en) 2009-12-18 2011-06-23 Idenix Pharmaceuticals, Inc. 5,5-fused arylene or heteroarylene hepatitis c virus inhibitors
EP2534170B1 (en) 2010-02-12 2017-04-19 Pharmascience Inc. Iap bir domain binding compounds
GB201106817D0 (en) 2011-04-21 2011-06-01 Astex Therapeutics Ltd New compound
WO2015091584A1 (en) * 2013-12-18 2015-06-25 F. Hoffmann-La Roche Ag Thiazolopyridine compounds, compositions and their use as tyk2 kinase inhibitors
LT3083616T (lt) 2013-12-20 2021-09-10 Astex Therapeutics Limited Bicikinių heterociklų junginiai ir jų panaudojimas terapijoje
CN105585583B (zh) * 2016-01-20 2018-04-13 广东工业大学 一种非肽类凋亡抑制蛋白拮抗剂及其合成方法与应用
CN105566447B (zh) * 2016-01-20 2019-09-20 广东工业大学 一种凋亡抑制蛋白的类肽拮抗剂及其合成方法与应用
CN106188098B (zh) * 2016-07-06 2017-11-03 广东工业大学 一种杂化抗癌药物及其制备方法与应用
JP7515175B2 (ja) 2018-07-31 2024-07-12 ファイメクス株式会社 複素環化合物
US20220402935A1 (en) 2019-07-31 2022-12-22 Fimecs, Inc. Heterocyclic compound
WO2021148396A1 (en) 2020-01-20 2021-07-29 Astrazeneca Ab Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
CN113402464A (zh) * 2021-03-15 2021-09-17 深圳市谦陌通辰实验有限公司 一种基于铃木反应的氟唑菌酰胺的合成方法
CN113149908A (zh) * 2021-04-08 2021-07-23 深圳市雁程化工有限公司 一种基于铃木反应的联苯吡菌胺的合成方法
US20230233691A1 (en) 2021-10-22 2023-07-27 University Of Houston System Methods and compositions for treating chronic inflammatory injury, metaplasia, dysplasia and cancers of epithelial tissues

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE430062B (sv) 1977-03-04 1983-10-17 Pharmacia Fine Chemicals Ab Kopplings- eller tioleringsreagens
DE2714880A1 (de) 1977-04-02 1978-10-26 Hoechst Ag Cephemderivate und verfahren zu ihrer herstellung
FR2575753B1 (fr) 1985-01-07 1987-02-20 Adir Nouveaux derives peptidiques a structure polycyclique azotee, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
DE3685626T2 (de) 1985-09-26 1993-01-28 Beckmann Research Inst Of The Sequenzierung von peptiden.
IT1226100B (it) * 1988-07-07 1990-12-10 Dompe Farmaceutici Spa Derivati benzimidazolici farmacologicamente attivi.
US4935494A (en) 1988-11-15 1990-06-19 City Of Hope C-terminal peptide and protein sequencing
DK167813B1 (da) 1989-12-07 1993-12-20 Carlbiotech Ltd As Pentapeptidderivat, farmaceutisk acceptable salte heraf, fremgangsmaade til fremstilling deraf og farmaceutisk praeparat indeholdende et saadant derivat
WO1992001938A1 (en) 1990-07-20 1992-02-06 City Of Hope Derivatization of c-terminal proline
RU2139731C1 (ru) 1992-11-13 1999-10-20 Айдек Фармасьютикалс Корпорейшн (US Способ лечения, антитела, гибридома
US5559209A (en) 1993-02-18 1996-09-24 The General Hospital Corporation Regulator regions of G proteins
US6335155B1 (en) 1998-06-26 2002-01-01 Sunesis Pharmaceuticals, Inc. Methods for rapidly identifying small organic molecule ligands for binding to biological target molecules
US6472172B1 (en) 1998-07-31 2002-10-29 Schering Aktiengesellschaft DNA encoding a novel human inhibitor-of-apoptosis protein
CA2355215A1 (en) 1998-12-28 2000-07-06 Jim Wells Identifying small organic molecule ligands for binding
US6916905B2 (en) * 2000-03-24 2005-07-12 The United States Of America As Represented By The Department Of Health And Human Services Dmt-Tic di-and tri-peptidic derivatives and related compositions and methods of use
US6608026B1 (en) 2000-08-23 2003-08-19 Board Of Regents, The University Of Texas System Apoptotic compounds
EP1315811A2 (en) 2000-08-24 2003-06-04 Thomas Jefferson University An iap binding peptide or polypeptide and methods of using the same
WO2002026775A2 (en) 2000-09-29 2002-04-04 Trustees Of Princeton University Compositions and methods for regulating apoptosis
US6992063B2 (en) 2000-09-29 2006-01-31 The Trustees Of Princeton University Compositions and method for regulating apoptosis
WO2002030959A2 (en) 2000-10-13 2002-04-18 Abbott Laboratories Peptides derived from smac (diablo) and methods of use therefor
AU2002253908A1 (en) 2001-02-08 2003-02-17 Thomas Jefferson University A conserved xiap-interaction motif in caspase-9 and smac/diablo for mediating apoptosis
MXPA03010762A (es) 2001-05-31 2005-03-07 Univ Princeton Peptidos enlazantes de iap y ensayos para identificar los compuestos que enlazan el iap.
US20030157522A1 (en) 2001-11-09 2003-08-21 Alain Boudreault Methods and reagents for peptide-BIR interaction screens
EP1495124A2 (en) 2002-04-17 2005-01-12 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Smac-peptides as therapeutics against cancer and autoimmune diseases
CA2491041A1 (en) 2002-07-02 2004-01-15 Novartis Ag Peptide inhibitors of smac protein binding to inhibitor of apoptosis proteins (iap)
ES2318167T3 (es) 2002-07-15 2009-05-01 The Trustees Of Princeton University Compuestos de union a iap.
WO2004017991A1 (en) 2002-08-13 2004-03-04 Cell Center Cologne Gmbh Use of iap for the diagnosis and of iap-inhibitors for the treatment of hodgkin’s lymphomas
US20040171554A1 (en) 2003-02-07 2004-09-02 Genentech, Inc. Compositions and methods for enhancing apoptosis
AU2003216203A1 (en) 2003-02-07 2004-09-06 Genentech, Inc. Compositions and methods for enhancing apoptosis
IL156263A0 (en) 2003-06-02 2004-01-04 Hadasit Med Res Service Livin-derived peptides, compositions and uses thereof
US7067274B2 (en) 2003-11-13 2006-06-27 Genentech, Inc. Compositions and methods for the screening pro-apoptotic compounds
US7932382B2 (en) 2004-01-16 2011-04-26 The Regents Of The University Of Michigan Conformationally constrained Smac mimetics and the uses thereof
CN1933847A (zh) 2004-01-16 2007-03-21 密歇根大学董事会 Smac肽模拟物及其应用
CA2582734C (en) 2004-03-01 2011-05-03 Board Of Regents, The University Of Texas System Dimeric small molecule potentiators of apoptosis
EP2253614B1 (en) * 2004-04-07 2012-09-19 Novartis AG Inhibitors of IAP
MXPA06014969A (es) 2004-07-02 2007-02-08 Genentech Inc Inhibidores de iap.
CA2573644A1 (en) 2004-07-12 2006-02-16 Idun Pharmaceuticals, Inc. Tetrapeptide analogs
EP1773766B1 (en) 2004-07-15 2014-04-02 Tetralogic Pharmaceuticals Corporation Iap binding compounds
ATE477254T1 (de) * 2004-12-20 2010-08-15 Genentech Inc Pyrrolidine als inhibitoren von iap
BRPI0607988A2 (pt) 2005-02-25 2009-10-27 Tetralogic Pharmaceuticals composto, composição farmacêutica, e método para induzir apoptose em uma célula
US7772177B2 (en) 2005-05-18 2010-08-10 Aegera Therapeutics, Inc. BIR domain binding compounds
JP2009512719A (ja) 2005-10-25 2009-03-26 アエゲラ セラピューティクス インコーポレイテッド Ｉａｐｂｉｒドメイン結合化合物
CN101374829A (zh) 2005-12-19 2009-02-25 健泰科生物技术公司 Iap的抑制剂
TWI543988B (zh) 2006-03-16 2016-08-01 科學製藥股份有限公司 結合於細胞凋亡抑制蛋白（ｉａｐ）之桿狀病毒ｉａｐ重複序列（ｂｉｒ）區域之化合物
CA2646186A1 (en) 2006-03-21 2007-11-29 Joyant Pharmaceuticals, Inc. Small molecule apoptosis promoters
WO2008014238A2 (en) 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
RU2009117701A (ru) 2006-10-12 2010-11-20 Новартис АГ (CH) Производные пирролидина в качестве ингибиторов iap

Also Published As

Publication number Publication date
IL191997A0 (en) 2008-12-29
RU2008129683A (ru) 2010-01-27
JP2009520041A (ja) 2009-05-21
US20090221630A1 (en) 2009-09-03
WO2007106192A2 (en) 2007-09-20
CN101374829A (zh) 2009-02-25
NZ594746A (en) 2013-03-28
US20120270886A1 (en) 2012-10-25
CA2632807A1 (en) 2007-09-20
AU2006340014A1 (en) 2007-09-20
EP1973899A2 (en) 2008-10-01
RU2451025C2 (ru) 2012-05-20
US8247557B2 (en) 2012-08-21
AU2006340014B2 (en) 2012-12-20
ZA200805152B (en) 2009-12-30
WO2007106192A3 (en) 2008-04-24
KR20080080203A (ko) 2008-09-02
JP5155184B2 (ja) 2013-02-27
EP1973899A4 (en) 2010-10-20

Similar Documents

Publication Publication Date Title
NO20083207L (no) Inhibitorer av IAP
NO20070606L (no) Inhibitorer av IAP
ATE433447T1 (de) Pyrimiidinverbindungen
NO20071719L (no) Pyridylinhibitorer for "hedgehog"-signalisering
NO20070557L (no) Ftalazinderivater som PARP-inhibitorer
NO20064763L (no) Forbindelser og fremgangsmater for behandling av dyslipidemi
ATE368031T1 (de) Neue gamma secretase inhibitoren
NO20073783L (no) Pyrrolidininhibitorer for IAP
NO20050525L (no) Benzimidazol-1-yl-tiofenforbindelser for behandling av cancer
SE0202539D0 (sv) Compounds
TW200510317A (en) Caspase inhibitors and uses thereof
EA200900152A1 (ru) Ингибиторы пирролотриазинкиназы
MX2010002938A (es) Derivados de (3-hidroxi-4-amino-butan-2-il)-3-(2-tiazol-2-il-pirro lidin-1-carbonil)benzamida y compuestos relacionados como inhibidores de beta-secretasa para tratar enfermedad de alzheimer.
NO20076145L (no) Ureadeviater, fremgangsmater for deres fremstilling og anvendelse derav
NO20060230L (no) Nye aminobenzofenonforbindelser
DK2054418T3 (da) Dihydrothieno-pyrimidiner som AKT-proteinkinase-inhibitorer
EA201170344A1 (ru) Азаиндольные ингибиторы iap
NO20073170L (no) Kaspaseinhibitorer og anvendelse derav
NO20044526L (no) Hemisterlinderivater og anvendelser derav
SE0303541D0 (sv) New compounds
MX2010007543A (es) Inhibidores de iap.
MX2009012525A (es) Pirazol-pirrolidinas como inhibidores de gamma secretasa.
MY138466A (en) Aminoalkoxyndoles as 5-ht6-receptor ligands for the treatment of cns-disorders
NO20054361D0 (no) Benzensylfonamidderivater, fremgangsmate for fremstilling og anvendelse derav for behandlig av smerte
MX2010000956A (es) Derivados de isoftalamida que inhiben actividad de beta-secretasa.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application